Expression of TCF3 in Wilms' tumor and its regulatory role in kidney tumor cell viability, migration and apoptosis in vitro

Abstract

Wilms' tumor (WT) is a major type of kidney cancer in children; however, the therapeutic measures for control of tumor metastasis, recurrence and death for this type of cancer remain unsatisfactory. The present study aimed to verify the expression of T-cell factor 3 (TCF3) in WT, and to explore its role in regulating the viability, migration and apoptosis of kidney tumor cells. Tumor tissues were collected from 10 patients with WT, and adjacent tissues were collected as normal controls. The expression levels of TCF3 were detected in WT tissues and adjacent tissues by reverse transcription-quantitative PCR (RT-qPCR), western blotting and immunohistochemistry. In addition, TCF3 expression was silenced in G401 kidney tumor cells via small interfering RNA transfection. Cell viability, cell cycle progression and cell apoptosis were assessed using the MTT assay and flow cytometry; the migration and invasion of kidney tumor cells were examined using Transwell and wound-healing assays; and the expression levels of Wnt signaling pathway-related genes (Wnt1, β-catenin and c-myc) were detected by RT-qPCR and western blotting. The results revealed that the expression levels of TCF3 were high in WT tissues from patients. Silencing TCF3 expression in G401 kidney tumor cells in vitro significantly inhibited cell viability and migration, and promoted cell apoptosis. Moreover, silencing TCF3 expression in G401 cells inhibited the expression levels of Wnt signaling pathway-related genes. Overall, these data indicated that TCF3 may be involved in WT development through regulation of Wnt signaling pathways. The findings of the present study provide a novel potential marker for the treatment and prognostic evaluation of WT.

RETRACTED: Identification of hub genes and construction of prognostic nomogram for patients with Wilms tumors

“…Novel biomarkers, therefore, are urgently needed in order to predict patients' prognosis and develop novel target-specific therapies. But the introduction of biology-driven approaches to risk stratification and new drug development has been slower in Wilms tumor than in other childhood tumors (7).It is very important to improving prognosis for Wilms tumor patients by improving treatment based on clinical and biological risk factors, and further stratification of current treatment options based on tumor biology (6,8).…”

FOXF2 Regulates PRUNE2 Transcription in the Pathogenesis of Colorectal Cancer

“…They were then stained with 3,3-diaminobenzidine (DAB, DA1015; Solarbio), counterstained with hematoxylin (G1140; Solarbio) for 5 min at room temperature and mounted with neutral gum after dehydration. 44 All slides were observed by a blinded investigator under a light microscope. Brown staining indicated immunoreactive (positive) cells; blue staining indicated nuclei.…”

A Pan-Cancer Analysis of the Oncogenic Role of Transcription Factor 3 in Human Tumors

“…It is reported that TCF3 is related to the development and progression of many human cancers, such as lung cancer [8],hepatocellular carcinoma [9],prostatic cancer [10],breast cancer [11],cervical carcinoma [12],nephroblastoma [13]and leukemia [14]. It has been reported that TCF3 is a common target of chromosome translocation in acute lymphoblastic leukemia, with multiple companion genes (PBX1, HLF, FB1) fused with TCF3 [14].…”